Kolon Life Science to Attend CPHI 2026...Expanding API and CDMO Businesses
Introduction of New API Items such as Phosphoramidite
Showcasing CDMO Capabilities in Process Development, Production, and Regulatory Compliance
Kolon Life Science announced on September 8 that it will participate with its own booth at 'CPHI Worldwide 2026', a global pharmaceutical industry exhibition to be held in Milan, Italy, from October 6 to 8 next month.
Aerial view of Kolon Life Science's booth at "CPHI Worldwide 2026." Kolon Life Science
View original imageAt this exhibition, Kolon Life Science plans to showcase its existing Active Pharmaceutical Ingredient (API) business as well as new supply items, and present its Contract Development and Manufacturing Organization (CDMO) services, which cover the entire process from research and development to production and regulatory compliance.
The company supplies APIs such as anti-inflammatory and analgesic agents and hyperlipidemia treatments to global markets, including Japan. It has undergone quality audits by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan and local pharmaceutical companies, and has strengthened its quality management system by obtaining Good Manufacturing Practice (GMP) certification from Brazil's National Health Surveillance Agency (ANVISA).
As a new API product, Kolon Life Science will introduce phosphoramidite, which is used in RNA therapeutics. The company plans to present basic phosphoramidites for DNA and RNA, a variety of modified products, and customer-tailored development solutions.
For the CDMO division, the company will introduce its business capabilities focused on customer-specific Chemistry, Manufacturing, and Controls (CMC) services, supporting processes ranging from process development to production and regulatory submissions. Based on its accumulated production and quality management expertise in the API business, the company plans to provide support from process design at the early development stage to commercial production.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Lee Hanguk, CEO of Kolon Life Science, said, "CPHI Worldwide 2026 will be an opportunity for Kolon Life Science to showcase its accumulated business competitiveness and broad portfolio to global clients. We will actively demonstrate our capabilities to respond to the diverse needs of our customers with customized solutions."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.